key: cord-0728510-3h165wae
authors: Hsueh, Po-Ren; Chen, Wen-Huei; Teng, Lee-Jene; Luh, Kwen-Tay
title: Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents
date: 2005-06-21
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2005.04.007
sha: 981522ef754275741825463e00a635b5902264e8
doc_id: 728510
cord_uid: 3h165wae

A rapid increase of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection (from 39% in 1991 to 75% in 2003) and vancomycin-resistant enterococci (VRE) (from 1.2% in 1996 to 6.1% in 2003) at a university hospital in Taiwan was found. The noticeable rise of MRSA and VRE was significantly correlated with the increased consumption of glycopeptides, β-lactam–β-lactamase inhibitor combinations, extended-spectrum cephalosporins, carbapenems and fluoroquinolones (Pearson's correlation coefficient, P < 0.05). Minimum inhibitory concentrations (MICs) of 100 non-duplicate blood isolates of MRSA (in 2003) and of 25 non-duplicate isolates of vancomycin-resistant Enterococcus faecalis and 172 vancomycin-resistant Enterococcus faecium (in 1996–2003) causing nosocomial infection recovered from various clinical specimens of patients treated at the hospital to nine antimicrobial agents were determined by the agar dilution method. All of these isolates were susceptible to linezolid and were inhibited by 0.5 mg/L of tigecycline, and all MRSA isolates were inhibited by daptomycin 1 mg/L, including two isolates of MRSA with heteroresistance to vancomycin. Daptomycin had two-fold better activity against vancomycin-resistant E. faecalis (MIC(90), 2 mg/L) than against vancomycin-resistant E. faecium (MIC(90), 4 mg/L). Decreased susceptibilities of vancomycin-resistant E. faecium and MRSA to quinupristin/dalfopristin (non-susceptibility 25% and 8%, respectively) were found. Telithromycin had poor activity against the isolates tested (MIC(90), 8 mg/L). Linezolid, daptomycin and tigecycline may represent therapeutic options for infections caused by these resistant Gram-positive organisms.

Antimicrobial drug resistance has become a great public health problem worldwide. Among the resistant Grampositive pathogens, methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate or * -resistant S. aureus (VISA or VRSA) and vancomycinresistant enterococci (VRE) are of great concern because of the importance of these organisms in causing various types of nosocomial infections [1] [2] [3] [4] [5] . Increases in the prevalence of these resistant pathogens in hospitals are frequently related to the high selective pressure of antibiotics, including extended-spectrum cephalosporins, fluoroquinolones and glycopeptides [1, 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] . Newer antimicrobial agents (oxazolidinones, daptomycin and streptogramins) with novel antimicrobial mechanisms have been developed to 0924 treat infections caused by these resistant Gram-positive bacteria [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Among these agents, linezolid was introduced in Taiwan in 2002, and quinupristin/dalfopristin and daptomycin will be available within the next few years. In Taiwan, the prevalence of MRSA in hospitals has been steadily increasing over the past decade [5, 18, 27] . Moreover, MRSA strains with reduced susceptibility to vancomycin, i.e. VISA and heterogeneously resistant VISA, and VRE, causing invasive nosocomial infections have been reported recently [4, 14] . This study aimed to describe the trend of increasing prevalence of MRSA and VRE at National Taiwan University Hospital (NTUH) from 1991 to 2003, to elucidate the relationship between annual antibiotic consumption at the hospital and the trends of resistance, and to determine the potential roles of some newer agents in the treatment of infections caused by these resistant pathogens.

NTUH is a 1800-bed university hospital located in northern Taiwan. The Nosocomial Infection Control Committee of the hospital was established in 1980 [5] . Definitions for nosocomial infection followed the National Nosocomial Infections Surveillance Guidelines [28] . The number of annual patient-days at the hospital increased from 360 210 in 1991 to 672 676 in 2002, but slightly decreased in 2003 (629 168) owing to the severe acute respiratory syndrome epidemic in Taiwan. The antimicrobial agent teicoplanin was introduced into the hospital in 1995 and the antibiotic linezolid in 2002. Quinupristin/dalfopristin, telithromycin and daptomycin were not available in the hospital during the study period.

Data on annual consumption (defined daily dose (DDD) per 1000 patient-days) of extended-spectrum cephalosporins (cefotaxime, ceftriaxone, ceftazidime, flumoxef, cefepime and cefpirome), ␤-lactam-␤-lactamase inhibitor combinations (ticarcillin/clavulanic acid and piperacillin/tazobactam), carbapenems (imipenem and meropenem), glycopeptides (vancomycin and teicoplanin), aminoglycosides (amikacin, gentamicin and tobramycin), injectable ciprofloxacin, all fluoroquinolones (ciprofloxacin (oral and injectable) and oral levofloxacin and moxifloxacin) and linezolid from 1991 to 2003 were obtained from the Pharmacy Department of the hospital. To determine the temporal trend of MRSA and VRE causing nosocomial infections at NTUH, data on the disk diffusion susceptibilities of S. aureus to oxacillin and of enterococci to vancomycin among isolates recovered from 1991 to 2003 were retrieved from the annual summary documents. Susceptibility testing for S. aureus and enterococci followed the National Committee for Clinical Laboratory Standards (NCCLS) guidelines [29] . Staphylococcus aureus ATCC 25923 and E. faecalis ATCC 29212 were used as control strains for routine disk susceptibility testing [29] . Methicillin resistance in S. aureus was routinely screened by growth of the isolate on a trypticase soy agar plate containing oxacillin 6 mg/L plus 2% NaCl and incubated in ambient air at 35 • C for 24 h [29] [30] [31] . Vancomycin resistance in enterococci was further confirmed by growth of the isolate on a brain heart infusion (BHI) agar with vancomycin 6 mg/L [29] [30] [31] and incubated in ambient air at 35 • C for 24 h. Staphylococcus aureus ATCC 29213, S. aureus ATCC 43300, E. faecalis ATCC 29212 and E. faecalis ATCC 51299 were used as control strains.

The minimum inhibitory concentrations (MICs) and susceptibility patterns were tested for 100 consecutive, nonduplicate blood isolates of MRSA from 100 patients who developed nosocomial bacteraemia at the hospital in 2003, and for 25 isolates of vancomycin-resistant E. faecalis and 172 isolates of vancomycin-resistant E. faecium from various clinical specimens of patients treated from 1996 to 2003. Two isolates of heteroresistant VISA from two patients with recurrent bacteraemia found in 2000-2002 were also included in this analysis [14] . The isolates were stored at −70 • C in trypticase soy broth (BBL Microbiology Systems, Cockeysville, MD, USA) supplemented with 15% glycerol before testing.

The following antimicrobial agents were provided by their manufacturers for use in this study: penicillin and tetracycline (Sigma Chemical Co., St Louis, MO, USA); oxacillin (Bristol-Myers Squibb, Princeton, NJ, USA); vancomycin (Eli Lilly & Co., Indianapolis, IN, USA); teicoplanin, quinupristin/dalfopristin and telithromycin (Aventis Pharma, Romainville, France); linezolid (Pharmacia, Kalamazoo, MI, USA); tigecycline (Wyeth-Ayerst, Pearl River, NY, USA); and daptomycin (Cubist Pharmaceuticals, Lexington, MA, USA).

MICs were determined for all isolates using the agar dilution method and the broth microdilution method (daptomycin only) according to the guidelines established by the NCCLS [30, 31] . The isolates were grown overnight on trypticase soy agar plates supplemented with 5% sheep blood (BBL Microbiology Systems) at 37 • C for 24 h. Bacterial inocula were prepared by suspending the freshly grown bacteria in sterile normal saline and adjusted to a 0.5 McFarland standard. For susceptibility testing of MRSA and VRE isolates for daptomycin, dry-form microtitre plates containing daptomycin with physiological concentrations of Ca 2+ (50 mg/L) manufactured by TREK Diagnostic Sys-tems (Cleveland, OH, USA) were used. For susceptibility testing of MRSA for oxacillin, Mueller-Hinton agar (BBL Microbiology Systems) supplemented with 2% NaCl was used [30] . For susceptibility testing of MRSA for other agents and for VRE, an unsupplemented Mueller-Hinton agar (BBL Microbiology Systems) was used. Using a Steers replicator, an organism density of 10 4 colony-forming units (CFU)/spot was inoculated onto an appropriate plate with various concentrations of antimicrobial agent and incubated at 35 • C for 24 h in ambient air.

Regular quality assurance was performed among isolate processing with the American Type Culture Collection (ATCC) as control strains: S. aureus ATCC 29213, S. aureus ATCC 43300, E. faecalis ATCC 29212 and E. faecalis ATCC 51299. Isolates were classified as susceptible, intermediate or resistant according to the NCCLS criteria [31] . Phenotypes (VanA, VanB or VanC) of VRE were defined as described previously [4] . There are no NCCLS MIC breakpoints for interpreting susceptibilities to telithromycin for Enterococcus species, or for tigecycline both for Enterococcus and Staphylococcus species [31] .

Pearson's correlation coefficient was used to determine the relationship of annual antibiotic consumption and annual rates of MRSA and VRE causing nosocomial infections. A P-value <0.05 was considered statistically significant. MICs of antimicrobial agents tested for the two control strains were within the ranges provided by the NCCLS. MICs against vancomycin-resistant E. faecium than against MRSA and vancomycin-resistant E. faecalis. All isolates tested were inhibited by tigecycline 0.5 mg/L, including MRSA and E. faecalis isolates that were highly resistant to tetracycline (MICs ≥ 128 mg/L). Tigecycline had 4-fold to 512-fold greater activity against vancomycin-resistant E. faecium isolates than tetracycline.

The two isolates of heteroresistant VISA were susceptible to quinupristin/dalfopristin and linezolid but highly resistant to tetracycline (MICs, 128 mg/L) and telithromycin (MICs > 32 mg/L). These two isolates both had daptomycin MICs of 1 mg/L and tigecycline MICs of 0.5 mg/L.

This study had two important findings. First, among the newer agents developed for the treatment of infections caused by drug-resistant Gram-positive bacteria, linezolid, daptomycin and tigecycline, but not quinupristin/dalfopristin, exhibited excellent in vitro activity both against MRSA and VRE isolates. Second, the stepwise increase of MRSA in the past 13 years and the emergence of VRE in past 7 years were significantly associated with the increasing hospital consumption of several classes of antimicrobial agents, particularly glycopeptides, ␤-lactam-␤-lactamase inhibitor combinations, extended-spectrum cephalosporins, carbapenems and fluoroquinolones (P < 0.05).

The relationship between antimicrobial use and the prevalence of MRSA causing nosocomial infections is complex. The positive correlation between the prevalence of MRSA and antibiotic use established at the level of the hospital unit is particularly strong for ␤-lactam antibiotics and fluoroquinolones [3, 6, 8, 10, 11, 32] . However, a positive correlation was also found with the use of carboxy-or ureido-penicillin and ceftazidime, cefsulodin, amoxicillin/clavulanic acid, macrolides and fluoroquinolones (levofloxacin or ciprofloxacin) [8, 10, 32] . Our findings were partly in accordance with previous observations [3, 6, 8, 10, 11, 32] . Interestingly, despite the vast increase in MRSA rates and the increases in antibiotic consumption, the organisms continued to be fully susceptible to vancomycin.

Antibiotic use is also able to influence nosocomial VRE epidemiology through different mechanisms [9] . High rates of vancomycin or third-generation cephalosporin use have been reported to be associated with increased prevalence of VRE in hospitals [1, 2, 9, 33, 34] . The risk of VRE colonisation varies during exposure to different ␤-lactam antimicrobials, with higher tendency to promote colonisation in cefotetan, ceftriaxone or ceftazidime [7, 12, 33] . Our study also confirmed that consumption of all fluoroquinolones (but not injectable ciprofloxacin alone) is positively correlated with an increased rate of VRE. Further research should be conducted to clarify this association.

The great majority of linezolid-and vancomycin-resistant E. faecium infections reported have occurred in patients treated with linezolid [35, 36] . Patients without prior exposure to linezolid could also acquire linezolid-and vancomycinresistant E. faecium infection via nosocomial transmission [36] . A 17% decline of linezolid susceptibility for vancomycin-resistant E. faecium was reported more than 6 months after its introduction into clinical use [35] . At our hospital, linezolid was introduced into clinical use in 2002. Although this drug was allowed in the treatment of VRE infections or in patients with MRSA infections refractory or intolerant to glycopeptide treatment, a five-fold increase in consumption was found in 2003 compared with 2002. Routine testing of linezolid susceptibility among these resistant Gram-positive bacteria, particularly among vancomycinresistant E. faecium isolates, is mandatory and has been performed in this hospital since 2004.

Eighty-six per cent of the MRSA isolates were resistant to telithromycin. This finding is in line with that of a previous global study (82%) [18] . Canton et al. demonstrated that MRSA isolates harbouring constitutive macrolide-lincosamide-streptogramin B mechanism (MLS B ) of resistance phenotype were also resistant to telithromycin [18] . Our previous study indicated that the majority of MRSA isolates in Taiwan were highly resistant to macrolides (MIC 50 > 128 mg/L) and possessed the MLS B phenotype [3] .

Our results on daptomycin susceptibility are generally comparable with other published data on clinical isolates from Europe and North American [19, 23, 25, 26] . All isolates of MRSA and 17 isolates (10%) of vancomycin-resistant E. faecium were not susceptible to daptomycin. Bacteraemia due to daptomycin-resistant MRSA (MIC, 2 mg/L) and emergence of daptomycin resistance (MICs ≥ 32 mg/L) in E. faecium during daptomycin therapy have been previously reported [37, 38] . Clinicians and microbiologists should be aware of the existence and the potential of the development of daptomycin resistance during therapy, although this agent is not available for clinical use in Taiwan [17] . These findings were not in agreement with our observations. All our MRSA isolates were inhibited by tigecycline 0.5 mg/L and all VRE isolates were inhibited at concentrations between 0.03 mg/L and 0.25 mg/L, independent of the species of enterococci, susceptibility to tetracycline and phenotype of resistance. Our results were in agreement with previous findings [16] [17] [18] 22, 23] .

Tigecycline has been proved to be active against drugresistant Gram-positive pathogens, including MRSA, VISA and VRE, and had better in vitro activities against these resistant organisms than daptomycin [17, 23] . Petersen et al. demonstrated that the activity of daptomycin (MIC 90 , 0.5 mg/L) could improve and equal that of tigecycline against MRSA strains if the test medium (Mueller-Hinton broth) was supplemented with adequate calcium (50-75 mg/L) [23] . In contrast, MIC 90 of daptomycin for MRSA and MICs of the two VISA isolates determined in the presence of 50 mg/L calcium in the test medium were two-fold higher than that of tigecycline.

Our report has two limitations. First, our data could not exclude the possibility that the increasing rate of MRSA may have been driving increased consumption, rather than the reverse, because the rate of MRSA was already high (70%) in 1996, when the DDD of glycopeptide was 50% of the consumption in 2003. Furthermore, the increased resistance could be a general trend (as is happening worldwide) and widespread use antimicrobials might contribute partly to this trend. Second, the rate of MRSA and VRE may be overestimated due to the possible hospital-wide dissemination of clonally-related isolates [4, 14, 39] . Failure to adhere to the guidelines from the Hospital Infection Control Practice Advisory Committee might result in an increase in hospitalacquired VRE [39] .

In conclusion, implementation of programmes to improve antimicrobial prescription practices as well as adherence to appropriate infection control measures to control the spread of MRSA and VRE are essential components of efforts to alleviate the growing prevalence of these multidrug-resistant pathogens in hospitals. Newer agents, such as linezolid, daptomycin and tigecycline, may represent therapeutic options for infections caused by these organisms.

The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units

Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci

Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from

Emergence of vancomycinresistant enterococci at a university hospital in Taiwan: persistence of multiple species and multiple clones

Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan

Methicillinresistant Staphylococcus aureus and antimicrobial use in Belgian hospitals

Third-generation cephalosporins and vancomycin as risk factors for postoperative vancomycin-resistant enterococcus infection

Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials

Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci

Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control

Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital

␤-Lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci

Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure

Vancomycin heteroresistance in methicillin-resistant Staphylococcus aureus

Eisenstein BI, the Daptomycin 98-01 and 99-01 Investigation. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

In vitro activities of glycylcycline GAR-946 against Gram-positive bacteria

Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000

Daptomycin in vitro susceptibility in European Gram-positive clinical isolates

Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria

Therapeutic and preventive options for the management of vancomycin-resistant enterococcal infections

In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens

Tigecycline 200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms

Daptomycin: a novel lipopeptide antibiotic

Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan

CDC definitions for nosocomial infections

Performance standards for antimicrobial disk susceptibility test; approved Standards M2-A8

Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically

Performance standards for antimicrobial susceptibility testing: 12th Informational Supplement: M100-S15

Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients

The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage

Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit

Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin

Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid

Daptomycin-resistant methicillin-resistant Staphylococcus aureus bacteremia

Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy

Control of vancomycinresistant enterococci in a hospital: a five-year experience in a Taiwanese teaching hospital